
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) – Zacks Research issued their Q1 2027 EPS estimates for Arrowhead Pharmaceuticals in a report released on Wednesday, November 18th. Zacks Research analyst D. Bautz anticipates that the biotechnology company will post earnings per share of ($1.39) for the quarter. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($5.07) per share. Zacks Research also issued estimates for Arrowhead Pharmaceuticals’ Q2 2027 earnings at ($1.42) EPS, Q3 2027 earnings at ($1.32) EPS, Q4 2027 earnings at ($1.64) EPS and FY2029 earnings at ($2.02) EPS.
Other analysts have also recently issued research reports about the stock. Morgan Stanley upped their target price on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. B. Riley Financial raised their price target on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Friday, November 13th. Stifel Nicolaus decreased their price objective on Arrowhead Pharmaceuticals from $104.00 to $96.00 and set a “buy” rating for the company in a research note on Friday, November 13th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Friday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $98.71.
Read Our Latest Report on Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Stock Performance
Arrowhead Pharmaceuticals stock opened at $43.65 on Friday. The company has a current ratio of 4.14, a quick ratio of 4.11 and a debt-to-equity ratio of 16.61. Arrowhead Pharmaceuticals has a 1 year low of $37.06 and a 1 year high of $95.49. The company has a market cap of $6.17 billion, a PE ratio of -8.54 and a beta of 1.34. The company’s 50-day moving average is $60.06 and its two-hundred day moving average is $70.49.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of ARWR. Optiver Holding B.V. increased its position in Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after buying an additional 186 shares during the last quarter. Versant Capital Management Inc lifted its position in shares of Arrowhead Pharmaceuticals by 285.1% in the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC lifted its position in shares of Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 154 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at approximately $39,000. Finally, Heritage Family Offices LLP acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at approximately $40,000. Institutional investors own 62.61% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.
Featured Stories
- Five stocks we like better than Arrowhead Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
